The estimated Net Worth of Edward J Mc Kinley is at least $4.76 Mille dollars as of 14 May 2014. Edward Kinley owns over 24,827 units of Clovis Oncology Inc stock worth over $4,762 and over the last 13 years Edward sold CLVS stock worth over $0.
Sign up
Edward Kinley CLVS stock SEC Form 4 insiders trading
Edward has made over 5 trades of the Clovis Oncology Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Edward exercised 24,827 units of CLVS stock worth $378,363 on 14 May 2014.
The largest trade Edward's ever made was buying 79,857 units of Clovis Oncology Inc stock on 21 November 2011 worth over $1,038,141. On average, Edward trades about 10,759 units every 57 days since 2011. As of 14 May 2014 Edward still owns at least 59,528 units of Clovis Oncology Inc stock.
You can see the complete history of Edward Kinley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Edward Kinley's mailing address?
Edward's mailing address filed with the SEC is C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO, 80301.
Insiders trading at Clovis Oncology Inc
Over the last 13 years, insiders at Clovis Oncology Inc have traded over $37,405,827 worth of Clovis Oncology Inc stock and bought 24,337,722 units worth $298,497,645 . The most active insiders traders include Forest Baskett, Scott D Sandell e Peter J Barris. On average, Clovis Oncology Inc executives and independent directors trade stock every 17 days with the average trade being worth of $8,863. The most recent stock trade was executed by Paul Edward Gross on 1 November 2022, trading 10,248 units of CLVS stock currently worth $820.
What does Clovis Oncology Inc's logo look like?
Complete history of Edward Kinley stock trades at Clovis Oncology Inc
Clovis Oncology Inc executives and stock owners
Clovis Oncology Inc executives and other stock owners filed with the SEC include:
-
Patrick J. Mahaffy,
Co-Founder, CEO, Pres & Exec. Director -
Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM,
Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer -
Patrick J. Mahaffy MA,
Co-Founder, CEO, Pres & Exec. Director -
Dr. Gillian C. Ivers-Read,
Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations -
Paul Edward Gross,
Exec. VP, Gen. Counsel & Sec. -
Daniel W. Muehl,
Exec. VP & CFO -
Dr. Gillian C. Ivers-Read BSc,
Co-Founder, Exec. VP & Chief Regulatory Officer -
Anna Sussman,
VP of Investor Relations -
Ann Bozeman,
Exec. VP of HR -
Breanna Burkart,
VP of Investor Relations & Corp. Communications -
Dr. Thomas Fuglsang Harding B.Sc., Ph.D.,
Exec. VP & Chief Scientific Officer -
Keith T. Flaherty,
Director -
Daniel W Muehl,
See Remarks -
Lindsey Rolfe,
See Remarks -
Thorlef Spickschen,
Director -
Paul H Klingenstein,
Director -
M James Barrett,
Director -
Gillian C Ivers Read,
See Remarks -
Ginger L Graham,
Director -
Corwin Dale Hooks,
See Remarks -
Edward J Mc Kinley,
Director -
Brian G Atwood,
Director -
Patrick J Mahaffy,
See Remarks -
Richard A. Fair,
Director -
Robert Azelby,
Director -
Paul Edward Gross,
See Remarks -
Erle T Mast,
Executive VP and CFO -
Enterprise Associates 13 Lp...,
-
Harry R Weller,
10% owner -
John C Reed,
Director -
Patrick J Kerins,
10% owner -
Kathleen K Schoemaker,
10% owner -
C Richard Kramlich,
10% owner -
Parters Vii L Pblair James ...,
-
Peter J Barris,
10% owner -
Brian H Dovey,
10% owner -
Steven L. Hoerter,
SEE REMARKS -
Jesse I Treu,
10% owner -
Ravi Viswanathan,
10% owner -
Partners 13, Limited Partne...,
-
Vii Associates Lp Dp,
10% owner -
Venture Capital Iv, L.P.Ver...,
-
David M Mott,
10% owner -
Scott D Sandell,
10% owner -
Brian K Halak,
10% owner -
Nicole Vitullo,
10% owner -
Vii Associates Lpblair Jame...,
-
Krishna Kittu Kolluri,
10% owner -
Ryan D Drant,
10% owner -
Parters Vii L P Domain,
10% owner -
Forest Baskett,
10% owner -
Enterprise Associates 13 Lp...,
10% owner -
James C Blair,
Director -
Thomas C. Harding,
See Remarks